Hairy Cell Leukemia Treatment (Professional) (cont.)
IN THIS ARTICLE
Treatment Option Overview
The initial therapies of choice are either cladribine (2-chlorodeoxyadenosine, 2-CdA) or pentostatin. These drugs have comparable response rates but have not been compared in phase III trials. Cladribine is administered as a one-time continuous infusion or series of subcutaneous injections and is associated with a high rate of febrile neutropenia.[2,3,4,5] Rarely, more than one course of treatment is required to induce a desirable response. Treatment should be discontinued once complete remission or stable partial remission with normalization of peripheral blood counts is reached. The presence of residual disease may be predictive of relapse but does not seem to affect survival.[4,6]
The role of consolidation or maintenance therapy in preventing relapse or progression of the disease following treatment with purine analogs has not been evaluated and remains unproven. Pentostatin is administered intermittently for a longer treatment duration but may result in a lower incidence of febrile complications.[7,8] While most patients remain disease free 10 years after treatment with these purine analogs, no patient has been followed long enough to assess cure.[9,10] Both nucleoside analogs cause profound suppression of CD4 counts, which may last for a year, and a potential increased risk of second malignancies has been reported.[4,11]
A study of 3,104 survivors of hairy cell leukemia from the SEER database showed an increased risk of second cancers (standardized incidence ratio = 1.24; 95% CI, 1.11–1.37), especially for Hodgkin and non-Hodgkin lymphomas. The increased risk for second cancers was seen even in the 2 decades prior to the introduction of purine nucleosides. With the use of cladribine, an increased risk of second malignancies is possible among patients with hairy cell leukemia (observed to expected ratio of about 1.8 in several series after 6 years).[4,11] Several series using pentostatin did not report an increased risk of second malignancies.[7,9,13] For a few patients, such as those with severe thrombocytopenia, splenectomy might be considered. After splenectomy, 50% of patients will require no additional therapy, and long-term survivors are common. Therapy with interferon-alpha is another treatment option, especially for patients with intercurrent infection.[8,15]
Hairy cell leukemia variant has a distinctive phenotype and typically presents with leukocytosis instead of leukopenia. These patients have poorer responses to initial cladribine, shorter durations of response, and typically do not respond again to purine analogues after relapse. Combinations of rituximab and purine analogues are under evaluation and further studies are required to define optimal therapies.[17,18]
eMedicineHealth Public Information from the National Cancer Institute
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Some material in CancerNet™ is from copyrighted publications of the respective copyright claimants. Users of CancerNet™ are referred to the publication data appearing in the bibliographic citations, as well as to the copyright notices appearing in the original publication, all of which are hereby incorporated by reference.